||||||||||CEL383 / Celsius Therap, Humira (adalimumab) / Eisai, AbbVie SINGLE CELL RNA SEQUENCING OF ULCERATIVE COLITIS AND CROHN’S DISEASE TISSUE SAMPLES INFORMS THE SELECTION OF TREM1 AS A TARGET FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES (Summit 8/9 - Gaylord Rockies) - Dec 23, 2022 - Abstract #CCCongress2023CCCongress_386; Our single cell RNA sequencing data provide further evidence that TREM1 is an exciting therapeutic target for UC and CD, with inhibition of TREM1 signaling expected to address pathology while maintaining an anti-bacterial response. We therefore developed a highly potent and selective monoclonal antibody inhibitor of TREM-1, CEL383, with the Phase 1 clinical trial expected to start in 2023.